Taken from: http://www.denverpost.com/news/ci_13981427?source=searchles


SAN ANTONIO — Some women with very advanced breast cancer might have a new treatment option. A combination of two drugs that more precisely target tumors significantly extended the lives of women who had stopped responding to other medicines, doctors reported Friday.

It was the first big test of combining Herceptin and Tykerb. In a study of 300 patients, women receiving both drugs lived nearly five months longer than those given Tykerb alone.

Doctors hope for an even bigger benefit in women with less-advanced disease and were elated at this much improvement for very sick women who were facing certain death.

"We don't see a lot that works in patients who have seen six prior therapies as they did in this trial, so that alone is exciting," said Dr. Jennifer Litton, a breast cancer specialist at the University of Texas M.D. Anderson Cancer Center.

The good results are in stark contrast to two other studies that found no survival advantage from Avastin, a drug whose approval for breast cancer patients was controversial.

Litton had no role in any of the studies, which were reported Friday at the San Antonio Breast Cancer Symposium.

Herceptin and Tykerb aim at a protein called HER-2 that is made in abnormally large quantities in about one-fourth of all breast cancers. Herceptin blocks the protein on the cell's surface; Tykerb does it inside the cell.

"It's kind of like having a double brake on your tumor," said Dr. Kimberly Blackwell of Duke University.

Blackwell led the combo treatment study and has consulted for its sponsor, British-based GlaxoSmithKline PLC, which makes Tykerb, and for Genentech, which makes Herceptin.